Nanogen, Inc. (NGEN) –
-
Life Science Investor Forum: Presentations Now Available for Online Viewing
-
Life Science Investor Forum Agenda Announced for June 22nd
-
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
-
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabil
-
Form D NERVGEN PHARMA CORP.
-
Form D/A NERVGEN PHARMA CORP.
-
Form D NERVGEN PHARMA CORP.
-
Form D/A NERVGEN PHARMA CORP.
-
Form D NERVGEN PHARMA CORP.
-
Form D NERVGEN PHARMA CORP.
-
Form D NERVGEN PHARMA CORP.
-
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
-
Life Science Company Live Investor Conference July 11th
-
NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th
-
OTC Markets Group Welcomes NervGen Pharma to OTCQX
-
Innovus Pharma Expands its Executive Management Team with the Addition of Randy Berholtz as its Executive Vice President, Corporate Development and General Counsel
-
Randy Berholtz Appointed to Hispanica International Delights of America, Inc. Board of Directors
-
Nanogen (NGEN) Reports a Q3 Loss; FY Guidance Unchanged
-
Nanogen (NGEN) and The Elitech Group Announce Merger Agreement
-
Nanogen (NGEN) Reports Q2 Loss of $0.07
-
Nanogen (NGEN) Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu
-
Nanogen (NGEN) Announces Consolidation of Point of Care Manufacturing Operations
-
Nanogen (NGEN) Announces Product Agreement with Thermo Fisher Scientific (TMO)
-
Nanogen (NGEN) Receives Stockholder Approval on Two of Three Proposals
-
Nanogen (NGEN) To Evaluate Strategic Alternatives for Microarray Business
-
Nanogen (NGEN) Announces $20M Financing
-
Nanogen (NGEN) Files $50M Mixed Shelf
-
Nanogen (NGEN) Surges on GSA Contract
-
Nanogen (NGEN) Awarded $4.5 Million Contract from U.S. CDC
-
Earnings Due Out After The Close 11/01/2006
-
Nanogen (NGEN) Announces Plans to Reduce North American Workforce by 15%
-
Drug Royalty Corp Buys Royalties from Nanogen (NGEN) for $20 Million
-
Nanogen (NGEN) and American Bio Medica (ABMC) Enter Supply Agreement
-
Nanogen (NGEN) Reports a Q1 Loss of $0.21
-
Earning Due Out After The Close Today And Before The Open Tomorrow
-
A Look At Yesterday�s Momentum Mover: NGEN, LEA, LBIX, and LANV
-
03/29 StreetInsider.com Unusual 11 Mid-Day Movers
-
03/29 Morning Momentum Movers: NGEN, LEA, LBIX, LANV
-
03/29 StreetInsider.com Pre-Open Movers
-
Nanogen (NGEN) Received 510(k) Clearance on StatusFirst From the FDA
-
03/16 StreetInsider.com Unusual 11 Mid-Day Movers
-
Nanogen (NGEN) Confirms Investment By Fisher Scientific
-
03/16 StreetInsider.com Pre-Open Movers
-
Fisher Scientific (FSH) to Acquire Athena Diagnostics For $283 Mln; Acquire 9% of Nanogen (NGEN)
-
NGEN Sells 6.8M Shares at $2.94/Sh
-
NGEN Awarded $2.5M Grant from US NIH
-
NGEN Says Study Using Nanogen Assay Confirms NT-proBNP
-
5/24: Streetinsider.com's Unusual 11 Afternoon Movers
-
5/24: Streetinsider.com's Unusual 8 Morning Movers
-
NGEN Issued Patents
Back to NGEN Stock Lookup